Join us to discuss this extension of the TUMORAPA trial - in a joint session with the #DermJC. Should kidney transplant recipients with squamous cell cancer be switched to sirolimus?
For this #NephJC, Samira Farouk, from the NSMC class of 2018 and a nephrology fellow from Mount Sinai, NY, has not only written an excellent summary - but also created the visual abstract, and will be hosting the chat next week.
We had a few hiccups for this chat: the authors, Komal Kumar, Betsy King did join us for the first chat - and so did some other staff from Hopkins ERGOT workgroup, but twitter gave a lot of troubles the next day. Tweets were not showing up - so we called it a day, and rescheduled the chat to Sep 28. Things did work out this time!
Back in fall 2015, we discussed one of the few positive trials in nephrology on #NephJC, on the use of therapeutic hypothermia for cooling deceased donors and the impact of subsequent graft function. To our pleasant surprise, a few weeks later, the lead author, Claus Niemann, replied in detail to our Pubmed Commons summary comment (see here).
A weeks ago, we noticed another comment on the same article, which pointed out that the record in clinicaltrials.gov had reported a different primary outcome, which indeed it did (primary outcome was terminal graft function in donor). We noted and tweeted out this comment, and the COMPARE group also replied.
But the story is not done yet. Today there is another comment on PubMedCommons, from Melissa Greenwald of the Health Resources and Services Administration, which funded the trial. From her review of documents, delayed graft function does seem to have been one of the primary outcomes, if not the main one. Read it and decide for yourself!
As always, great job by Hector!